Analysis of potential receptor tyrosine kinase targets in intimal and mural sarcomas

Journal of Pathology

Volumn 212, Issue 2, 2007, Pages 227-235

  Tamborini, E ^a   Casieri, P ^a   Miselli, F ^a   Orsenigo, M ^a   Negri, T ^a   Piacenza, C ^a   Stacchiotti, S ^a   Gronchi, A ^a   Pastorino, U ^a   Pierotti, M A ^a   Pilotti, Silvana ^a  

^a NATIONAL CANCER INSTITUTE   (Italy)

Author keywords

Gene amplification; Intimal sarcoma; Mural sarcoma; RTK activation profile

Indexed keywords

ANTHRACYCLINE; DOCETAXEL; DOXORUBICIN; EPIDERMAL GROWTH FACTOR RECEPTOR; GEMCITABINE; IFOSFAMIDE; PLATELET DERIVED GROWTH FACTOR ALPHA RECEPTOR; PLATELET DERIVED GROWTH FACTOR BETA RECEPTOR; PROTEIN TYROSINE KINASE; STEM CELL FACTOR RECEPTOR;

ADJUVANT THERAPY; ADULT; ARTICLE; CANCER GRADING; CANCER RADIOTHERAPY; CANCER SURGERY; CASE REPORT; CHEMICAL ANALYSIS; CHROMOSOME ANALYSIS; CONTROLLED STUDY; DEREGULATION; DISOMY; FEMALE; FLUORESCENCE IN SITU HYBRIDIZATION; GENE AMPLIFICATION; GENE CLUSTER; GENE MUTATION; GENE SEQUENCE; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; IMMUNOPHENOTYPING; IMMUNOPRECIPITATION; INTIMA; LEIOMYOSARCOMA; MALE; MORPHOLOGY; MULTIPLE CYCLE TREATMENT; NUMERICAL CHROMOSOME ABERRATION; PREDICTION; PRIORITY JOURNAL; PROTEIN INDUCTION; PROTEIN TARGETING; SARCOMA; VASCULAR TUMOR; WESTERN BLOTTING;

ADULT; BLOTTING, WESTERN; CORONARY VESSELS; FEMALE; GENE AMPLIFICATION; HEART NEOPLASMS; HUMANS; IMMUNOHISTOCHEMISTRY; IMMUNOPHENOTYPING; IMMUNOPRECIPITATION; IN SITU HYBRIDIZATION, FLUORESCENCE; LIGANDS; MALE; MIDDLE AGED; PROTO-ONCOGENE PROTEINS C-KIT; RECEPTOR PROTEIN-TYROSINE KINASES; RECEPTOR, EPIDERMAL GROWTH FACTOR; RECEPTOR, PLATELET-DERIVED GROWTH FACTOR ALPHA; RECEPTOR, PLATELET-DERIVED GROWTH FACTOR BETA; SARCOMA;

EID: 34249848684     PISSN: 00223417     EISSN: 10969896     Source Type: Journal    
DOI: 10.1002/path.2177     Document Type: Article

References (17)

1. Burke AP, Virmani R. Sarcomas of the great vessels. A clinicopathologic study. Cancer 1993;71:1761-1773.
2. Sebenik M, Ricci A Jr, DiPasquale B, Mody K, Pytel P, Jee KJ, et al. Undifferentiated intimal sarcoma of large systemic blood vessels: report of 14 cases with immunohistochemical profile and review of the literature. Am J Surg Pathol 2005;29:1184-1193.
3. Huo L, Moran CA, Fuller GN, Gladish G, Suster S. Pulmonary artery sarcoma: a clinicopathologic and immunohistochemical study of 12 cases. Am J Clin Pathol 2006;125:419-424.
4. Bode-Lesniewska B, Zhao J, Speel EJ, Biraima AM, Turina M, Komminoth P, et al. Gains of 12q13-14 and overexpression of mdm2 are frequent findings in intimal sarcomas of the pulmonary artery. Virchows Arch 2001;438:57-65.
5. Zhao J, Roth J, Bode-Lesniewska B, Pfaltz M, Heitz PU, Komminoth P. Combined comparative genomic hybridization and genomic microarray for detection of gene amplifications in pulmonary artery intimal sarcomas and adrenocortical tumors. Genes Chromosomes Cancer 2002; 34:48-57.
6. Higgins R, Posner MC, Moosa HH, Staley C, Pataki KI, Mendelow H. Mesenteric infarction secondary to tumor emboli from primary aortic sarcoma. Guidelines for diagnosis and management. Cancer 1991; 68:1622-1627.
7. Pilotti S, Della Torre G, Lavarino C, Di Palma S, Sozzi G, Minoletti F, et al. Distinct mdm2/p53 expression patterns in liposarcoma subgroups: implications for different pathogenetic mechanisms. J Pathol 1997;181:14-24.
8. Pilotti S, Della Torre G, Lavarino C, Sozzi G, Minoletti F, Vergani B, et al. Molecular abnormalities in liposarcoma: role of MDM2 and CDK4-containing amplicons at 12q13-22. J Pathol 1998; 185:188-190.
9. Lavarino C, Pilotti S, Oggionni M, Gatti L, Perego P, Bresciani G, et al. p53 gene status and response to platinum/paclitaxel-based chemotherapy in advanced ovarian carcinoma. J Clin Oncol 2000; 18:3936-3945.
10. Bode-Lesniewska B, Komminoth P. Intimal sarcoma. World Health Organization Classification of Tumours. Oathology and Genetics of Tumors of Soft Tissue and Bone. IACR Press:Lyon, 2002; 223-224.
11. Lagonigro MS, Tamborini E, Negri T, Staurengo S, Dagrada GP, Miselli F, et al. PDGFRalpha, PDGFRbeta and KIT expression/activation in conventional chondrosarcoma. J Pathol 2006;208:615-623.
12. Hirsch FR, Varella-Garcia M, McCoy J, West H, Xavier AC, Gumerlock P, et al. Southwest Oncology Group. Increased epidermal growth factor receptor gene copy number detected by fluorescence in situ hybridization associates with increased sensitivity to gefitinib in patients with bronchioloalveolar carcinoma subtypes: a Southwest Oncology Group Study. J Clin Oncol 2005;23:6838-6845.
13. Chung CH, Ely K, McGavran L, Varella-Garcia M, Parker J, Parker N, et al. Increased epidermal growth factor receptor gene copy number is associated with poor prognosis in head and neck squamous cell carcinomas. J Clin Oncol 2006;24:4170-4176.
14. Tamborini E, Bonadiman L, Greco A, Albertini V, Negri T, Gronchi A, et al. A new mutation in the KIT ATP pocket causes acquired resistance to imatinib in a gastrointestinal stromal tumor patient. Gastroenterology 2004;127:294-299.
15. Negri T, Casieri P, Miselli F, Orsenigo M, Piacenza C, Stacchiotti S, et al. PDGFRA, PDGFRB and KIT deregulation in a NSCLC patient. Br J Cancer 2007;96:180-181.
16. Sordella R, Bell DW, Haber DA, Settleman J. Gefitinib-sensitizing EGFR mutations in lung cancer activate anti-apoptotic pathways. Science 2004;305:1163-1167. Epub 2004 Jul 29.
17. Felli N, Fontana L, Pelosi E, Botta R, Bonci D, Facchiano F, et al. MicroRNAs 221 and 222 inhibit normal erythropoiesis and erythroleukemic cell growth via kit receptor down-modulation. Proc Natl Acad Sci U S A 2005;102:18081-18086. Epub 2005 Dec 5.